Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEH1 | O60930 | 2/20 | 0.60 |
| ▸ | PDE5A | O76074 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 2/20 | 0.47 |
| ▸ | KDM5A | P29375 | 2/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTPRG | P23470 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405065 | 0.87 | PDE5A (0.64) | RNASEH1PDE5APOLBKMT2AACVR1 | |
| SCHEMBL405327 | 0.84 | KMT2A (0.61) | RNASEH1PDE5APOLBKMT2AKDM4E | |
| SCHEMBL404377 | 0.82 | RNASEH1 (0.60) | RNASEH1PDE5APOLBKDM4AKDM5A | |
| SCHEMBL405407 | 0.81 | POLB (0.57) | RNASEH1PDE5APOLBKDM4ELMNA | |
| SCHEMBL400190 | 0.80 | KDM4C (0.52) | KDM5B | |
| SCHEMBL405713 | 0.78 | ALDH1A1 (0.48) | RNASEH1PDE5APOLBKMT2AACVR1 | |
| SCHEMBL403310 | 0.77 | PDE5A (0.62) | RNASEH1PDE5APOLBKDM4AKDM5A | |
| SCHEMBL13892327 | 0.76 | TNKS2 (0.57) | POLBKMT2AMAPTACVR1PARP1 | |
| SCHEMBL401655 | 0.76 | PDE5A (0.74) | RNASEH1PDE5APOLBKDM4AKDM5A | |
| SCHEMBL404756 | 0.74 | KDM4E (0.64) | POLBMAPTKDM4ELMNAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050739-B1 | QUINAZOLINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2016-07-06 | — | — | EP | disclosed |
| CN-101501007-B | Quinazoline derivative | ASKA PARMACEUTICAL CO LTD | 2014-01-29 | — | — | CN | disclosed |
| US-8101624-B2 | Quinazoline derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20090318478-A1 | QUINAZOLINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-2050739-A1 | QUINAZOLINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | RNASEH1 974/4885PDE5A 14/4885POLB 555/4885 |
| US-20090318478-A1 | QUINAZOLINE DERIVATIVES | PDE9A, PDE3A, PDE5A | RNASEH1 254/4885PDE5A 3/4885POLB 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.